Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation” March 05, 2021Vol.47 No.09By Paul Goldberg
NASEM: Reduce cancer drug waste by reformulating development, payments, dosing March 05, 2021Vol.47 No.09By Alexandria Carolan
Cancer History ProjectFree A 25-year retrospective: How NCCN changed the way cancer medicine is practiced—and paid for March 05, 2021Vol.47 No.09By Paul Goldberg
FreeIn the Archives Joseph H. Ogura, Arti Hurria, and the impact of the National Cancer Act February 26, 2021Vol.47 No.08
FreeGuest Editorial Reflections on J Freireich and Baruch Spinoza: Can one be too smart? February 26, 2021Vol.47 No.08By Robert Peter Gale
Conversation with The Cancer Letter Kunle Odunsi: 50 years from now disparities—and metastatic disease—will be gone February 26, 2021Vol.47 No.08By Robert A. Winn
Free The Bidens announce initiatives on health inequity and DARPA-like research for cancer February 26, 2021Vol.47 No.08By Matthew Bin Han Ong
Conversation with The Cancer LetterFree A $250M gift creates Break Through Cancer foundation to focus five cancer centers on hard-to-treat diseases February 25, 2021Vol.47 No.08By Matthew Bin Han Ong and Paul Goldberg
FreeTrials & Tribulations City of Hope leads Cancer Patients Bill of Rights resolution, aimed at expanding access to unleash the full benefits of cancer care innovation February 19, 2021Vol.47 No.07By Harlan Levine and Joseph Alvarnas
